Doxorubicin octanoylhydrazone | CAS# 76634-98-5 | Biochemical

MedKoo Cat#: 573931 | Name: Doxorubicin octanoylhydrazone

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Doxorubicin octanoylhydrazone is an anthracycline antibiotic with antineoplastic activity.

Chemical Structure

Doxorubicin octanoylhydrazone

CAS#76634-98-5

Theoretical Analysis

MedKoo Cat#: 573931

Name: Doxorubicin octanoylhydrazone

CAS#: 76634-98-5

Chemical Formula: C35H45N3O11

Exact Mass: 683.3054

Molecular Weight: 683.76

Elemental Analysis: C, 61.48; H, 6.63; N, 6.15; O, 25.74

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.

Bulk Inquiry

Related CAS #

No Data

Synonym

Doxorubicin octanoylhydrazone

IUPAC/Chemical Name

N'-((E)-1-((2S,4S)-4-(((4S,5S,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-2,5,12-trihydroxy-7-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-2-yl)-2-hydroxyethylidene)octanehydrazide

InChi Key

YFNRFXHHYCNVGO-AFZQDIHDSA-N

InChi Code

1S/C35H45N3O11/c1-4-5-6-7-8-12-24(40)38-37-23(16-39)35(46)14-19-27(22(15-35)49-25-13-20(36)30(41)17(2)48-25)34(45)29-28(32(19)43)31(42)18-10-9-11-21(47-3)26(18)33(29)44/h9-11,17,20,22,25,30,39,41,43,45-46H,4-8,12-16,36H2,1-3H3,(H,38,40)/b37-23+/t17-,20-,22-,25?,30+,35-/m0/s1

SMILES Code

CCCCCCCC(=O)N/N=C(\CO)/[C@@]1(Cc2c(c(c3c(c2O)C(=O)c4cccc(c4C3=O)OC)O)[C@H](C1)OC5C[C@@H]([C@@H]([C@@H](O5)C)O)N)O

Appearance

Solid powder

Purity

>98% (or refer to the Certificate of Analysis)

Shipping Condition

Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition

Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility

Soluble in DMSO

Shelf Life

>3 years if stored properly

Drug Formulation

This drug may be formulated in DMSO

Stock Solution Storage

0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code

2934.99.9001

More Info

Instruction

View handling instruction

Preparing Stock Solutions

The following data is based on the product molecular weight 683.76 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Concentration / Solvent Volume / Mass	1 mg	5 mg	10 mg
1 mM	1.15 mL	5.76 mL	11.51 mL
5 mM	0.23 mL	1.15 mL	2.3 mL
10 mM	0.12 mL	0.58 mL	1.15 mL
50 mM	0.02 mL	0.12 mL	0.23 mL

1: Zhong YJ, Shao LH, Li Y. Cathepsin B-cleavable doxorubicin prodrugs for targeted cancer therapy (Review). Int J Oncol. 2013 Feb;42(2):373-83. doi: 10.3892/ijo.2012.1754. Epub 2012 Dec 28. Review. PubMed PMID: 23291656; PubMed Central PMCID: PMC3583876. 2: Xi L, Zhu SG, Das A, Chen Q, Durrant D, Hobbs DC, Lesnefsky EJ, Kukreja RC. Dietary inorganic nitrate alleviates doxorubicin cardiotoxicity: mechanisms and implications. Nitric Oxide. 2012 May 15;26(4):274-84. doi: 10.1016/j.niox.2012.03.006. Epub 2012 Apr 5. Review. PubMed PMID: 22484629; PubMed Central PMCID: PMC3360792. 3: Octavia Y, Tocchetti CG, Gabrielson KL, Janssens S, Crijns HJ, Moens AL. Doxorubicin-induced cardiomyopathy: from molecular mechanisms to therapeutic strategies. J Mol Cell Cardiol. 2012 Jun;52(6):1213-25. doi: 10.1016/j.yjmcc.2012.03.006. Epub 2012 Mar 21. Review. PubMed PMID: 22465037. 4: Prados J, Melguizo C, Ortiz R, VÃ©lez C, Alvarez PJ, Arias JL, RuÃz MA, Gallardo V, Aranega A. Doxorubicin-loaded nanoparticles: new advances in breast cancer therapy. Anticancer Agents Med Chem. 2012 Nov;12(9):1058-70. Review. PubMed PMID: 22339066. 5: Airoldi M, Amadori D, Barni S, Cinieri S, De Placido S, Di Leo A, Gennari A, Iacobelli S, Ionta MT, Lorusso V, Lotrionte M, Marchetti P, Mattioli R, Minotti G, Pronzato P, Rosti G, Tondini CA, Veronesi A. Clinical activity and cardiac tolerability of non-pegylated liposomal doxorubicin in breast cancer: a synthetic review. Tumori. 2011 Nov-Dec;97(6):690-2. doi: 10.1700/1018.11082. Review. PubMed PMID: 22322832. 6: Khasraw M, Bell R, Dang C. Epirubicin: is it like doxorubicin in breast cancer? A clinical review. Breast. 2012 Apr;21(2):142-9. doi: 10.1016/j.breast.2011.12.012. Epub 2012 Jan 17. Review. PubMed PMID: 22260846. 7: Rakowski JA, Ahmad S, Holloway RW. Use of pegylated liposomal doxorubicin in the management of platinum-sensitive recurrent ovarian cancer: current concepts. Expert Rev Anticancer Ther. 2012 Jan;12(1):31-40. doi: 10.1586/era.11.187. Review. PubMed PMID: 22149430. 8: Duggan ST, Keating GM. Pegylated liposomal doxorubicin: a review of its use in metastatic breast cancer, ovarian cancer, multiple myeloma and AIDS-related Kaposi's sarcoma. Drugs. 2011 Dec 24;71(18):2531-58. doi: 10.2165/11207510-000000000-00000. Review. PubMed PMID: 22141391. 9: Meng L, Zhang X, Lu Q, Fei Z, Dyson PJ. Single walled carbon nanotubes as drug delivery vehicles: targeting doxorubicin to tumors. Biomaterials. 2012 Feb;33(6):1689-98. doi: 10.1016/j.biomaterials.2011.11.004. Epub 2011 Dec 2. Review. PubMed PMID: 22137127. 10: Maeda M, Mabuchi S, Matsumoto Y, Hisamatsu T, Ohashi H, Kimura T. Activity of pegylated liposomal doxorubicin for extragenital mullerian adenosarcoma with sarcomatous overgrowth: a case report and a review of the literature. Eur J Gynaecol Oncol. 2011;32(5):542-6. Review. PubMed PMID: 22053671.